Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of rebastinib when
combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced
breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University Deciphera Pharmaceuticals LLC